77 related articles for article (PubMed ID: 20666954)
1. Levonorgestrel-intrauterine system effects on hemostasis and menstrual blood loss in women seeking contraception.
Koh SC; Singh K
J Obstet Gynaecol Res; 2010 Aug; 36(4):838-44. PubMed ID: 20666954
[TBL] [Abstract][Full Text] [Related]
2. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia.
Koh SC; Singh K
J Thromb Haemost; 2007 Jan; 5(1):133-8. PubMed ID: 17010149
[TBL] [Abstract][Full Text] [Related]
3. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding.
Crosignani PG; Vercellini P; Mosconi P; Oldani S; Cortesi I; De Giorgi O
Obstet Gynecol; 1997 Aug; 90(2):257-63. PubMed ID: 9241305
[TBL] [Abstract][Full Text] [Related]
4. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
[TBL] [Abstract][Full Text] [Related]
5. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
[TBL] [Abstract][Full Text] [Related]
6. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
Hidalgo MM; Hidalgo-Regina C; Bahamondes MV; Monteiro I; Petta CA; Bahamondes L
Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221
[TBL] [Abstract][Full Text] [Related]
7. Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium.
Papp C; Schatz F; Krikun G; Hausknecht V; Lockwood CJ
Early Pregnancy (Cherry Hill); 2000 Oct; 4(4):230-9. PubMed ID: 11742418
[TBL] [Abstract][Full Text] [Related]
8. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
[TBL] [Abstract][Full Text] [Related]
9. Menstrual blood loss in women using the frameless FibroPlant LNG-IUS.
Andrade A; Wildemeersch D
Contraception; 2009 Feb; 79(2):134-8. PubMed ID: 19135571
[TBL] [Abstract][Full Text] [Related]
10. A biological model for the regulation of peri-implantational hemostasis and menstruation.
Lockwood CJ; Schatz F
J Soc Gynecol Investig; 1996; 3(4):159-65. PubMed ID: 8796825
[TBL] [Abstract][Full Text] [Related]
11. Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells.
Guan YM; Carlberg M; Bruse C; Carlström K; Bergqvist A
Acta Obstet Gynecol Scand; 2002 May; 81(5):389-97. PubMed ID: 12027810
[TBL] [Abstract][Full Text] [Related]
12. Assessment of menstrual blood loss in Belgian users of a new T-shaped levonorgestrel-releasing intrauterine system.
Wildemeersch D; Rowe PJ
Contraception; 2005 Jun; 71(6):470-3. PubMed ID: 15914139
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Levonorgestrel on Fibrinolytic Factors in Human Endometrial Endothelial Cells.
Pakrashi T; Taylor JE; Nelson A; Archer DF; Jacot T
Reprod Sci; 2016 Nov; 23(11):1536-1541. PubMed ID: 27130232
[TBL] [Abstract][Full Text] [Related]
14. Regulation of plasminogen activator inhibitor 1 expression by interaction of epidermal growth factor with progestin during decidualization of human endometrial stromal cells.
Lockwood CJ
Am J Obstet Gynecol; 2001 Apr; 184(5):798-804; discussion 804-5. PubMed ID: 11303186
[TBL] [Abstract][Full Text] [Related]
15. von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator.
Schved JF; Gris JC; Arnaud A; Martinez P; Sanchez N; Wautier JL; Sarlat C
J Lab Clin Med; 1992 Sep; 120(3):411-9. PubMed ID: 1517688
[TBL] [Abstract][Full Text] [Related]
16. Intrauterine devices: an effective alternative to oral hormonal contraception.
Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection.
Rauramo I; Elo I; Istre O
Obstet Gynecol; 2004 Dec; 104(6):1314-21. PubMed ID: 15572496
[TBL] [Abstract][Full Text] [Related]
18. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas.
Magalhães J; Aldrighi JM; de Lima GR
Contraception; 2007 Mar; 75(3):193-8. PubMed ID: 17303488
[TBL] [Abstract][Full Text] [Related]
19. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
20. Progestin-releasing intrauterine systems.
Luukkainen T; Pakarinen P; Toivonen J
Semin Reprod Med; 2001 Dec; 19(4):355-63. PubMed ID: 11727177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
